Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
isatuximab + SAR439459 + dexamethasone
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**isatuximab + SAR439459 + dexamethasone** is a combination regimen under clinical investigation for the treatment of relapsed or refractory multiple myeloma. Isatuximab is a monoclonal antibody targeting CD38 on malignant plasma cells, leading to cell death via immune effector mechanisms and direct apoptosis. SAR439459 is an investigational agent targeting the transforming growth factor beta (TGF-beta) pathway, potentially counteracting immunosuppressive tumor microenvironments and enhancing anti-tumor immune responses. Dexamethasone is a synthetic glucocorticoid used as a backbone agent in myeloma regimens for its anti-inflammatory and cytotoxic effects on plasma cells. This combination is studied to evaluate synergistic benefit in advanced myeloma patients who have previously received multiple therapies, with endpoints including safety, efficacy (response rates), progression-free survival, and overall survival[1][6].
- Other names
- isatuximab + SAR439459 + dexamethasone
02
Targets
CD38 (Cluster of Differentiation 38)GR (Glucocorticoid receptor)TGFB (GARP–latent transforming growth factor beta 1 complex)
Beyond the preview
Go deeper on isatuximab + SAR439459 + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on isatuximab + SAR439459 + dexamethasone.